Literature DB >> 15047561

Antimicrobial susceptibility and mechanisms of resistance to quinolones and beta-lactams in Acinetobacter genospecies 3.

A Ribera1, F Fernández-Cuenca, A Beceiro, G Bou, L Martínez-Martínez, A Pascual, J M Cisneros, J Rodríguez-Baño, J Pachón, J Vila.   

Abstract

Antimicrobial susceptibility was determined in 15 epidemiologically unrelated clinical isolates of Acinetobacter genospecies 3. Moreover, the mechanisms of resistance to some beta-lactam antibiotics may be associated with the presence of a chromosomal cephalosporinase, AmpC, and the resistance to quinolones related to mutations in the gyrA and parC genes.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15047561      PMCID： PMC375291          DOI： 10.1128/AAC.48.4.1430-1432.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates.

Authors:  Anna Ribera; Joaquim Ruiz; M Teresa Jiminez de Anta; Jordi Vila
Journal:  J Antimicrob Chemother       Date:  2002-04       Impact factor: 5.790

2.  Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6).

Authors:  W H Traub; M Spohr
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

4.  Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

Authors:  Caroline J Henwood; Tess Gatward; Marina Warner; Dorothy James; Mark W Stockdale; Richard P Spence; Kevin J Towner; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

5.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Authors:  H Wisplinghoff; M B Edmond; M A Pfaller; R N Jones; R P Wenzel; H Seifert
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

6.  Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics.

Authors:  Cristina Danes; Margarita M Navia; Joaquim Ruiz; Francesc Marco; Angels Jurado; M Teresa Jimenez de Anta; Jordi Vila
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

7.  Antimicrobial susceptibility of Acinetobacter species.

Authors:  H Seifert; R Baginski; A Schulze; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Clinical strains of Acinetobacter classified by DNA-DNA hybridization.

Authors:  I Tjernberg; J Ursing
Journal:  APMIS       Date:  1989-07       Impact factor: 3.205

9.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  Significance of genomic DNA group delineation in comparative studies of antimicrobial susceptibility of Acinetobacter spp.

Authors:  Elizabeth T S Houang; Yiu Wai Chu; K Y Chu; K C Ng; C M Leung; A F B Cheng
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  6 in total

1.  Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.

Authors:  Sara Marti; Javier Sánchez-Céspedes; M Dolores Blasco; Marc Ruiz; Paula Espinal; Verónica Alba; Felipe Fernández-Cuenca; Alvaro Pascual; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

2.  OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different Acinetobacter species isolated during a nosocomial outbreak.

Authors:  María Merino; Joshi Acosta; Margarita Poza; Francisca Sanz; Alejandro Beceiro; Fernando Chaves; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

3.  DNA microarray for genotyping antibiotic resistance determinants in Acinetobacter baumannii clinical isolates.

Authors:  Simon Dally; Karin Lemuth; Martin Kaase; Steffen Rupp; Cornelius Knabbe; Jan Weile
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Clinical features of infections and colonization by Acinetobacter genospecies 3.

Authors:  José Molina; José Miguel Cisneros; Felipe Fernández-Cuenca; Jesús Rodríguez-Baño; Anna Ribera; Alejandro Beceiro; Luis Martínez-Martínez; Álvaro Pascual; Germán Bou; Jordi Vila; Jerónimo Pachón
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

5.  Antimicrobial susceptibility and mechanisms of resistance in Shigella and Salmonella isolates from children under five years of age with diarrhea in rural Mozambique.

Authors:  Inácio Mandomando; Dinis Jaintilal; Maria J Pons; Xavier Vallès; Mateu Espasa; Laura Mensa; Betuel Sigaúque; Sergi Sanz; Jahit Sacarlal; Eusébio Macete; Fátima Abacassamo; Pedro L Alonso; Joaquim Ruiz
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

6.  Genetic variability among ampC genes from acinetobacter genomic species 3.

Authors:  Alejandro Beceiro; Astrid Pérez; Felipe Fernández-Cuenca; Luis Martínez-Martínez; Alvaro Pascual; Jordi Vila; Jesús Rodríguez-Baño; Jose Miguel Cisneros; Jerónimo Pachón; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.